-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There are hundreds of clinical targets around the world every year, but very few of them can finally tap great potential
.
Do you want to know what targets each year imply huge opportunities?
What are the TOP25 Targets of Medical Rubik's Cube Translational Medicine?
What are the TOP25 Targets of Medical Rubik's Cube Translational Medicine? Medicine Rubik's Cube has been paying close attention to the new targets and new mechanisms of global drug development.
Based on the NextPharma database - translational medicine data, we will select 25 targets that have made major breakthroughs in the previous year at the beginning of each year.
The selection criteria are mainly divided into 3 objective Dimensions: 1) A new target with clinical translation value confirmed for the first time; 2) A target that has passed clinical POC verification for the first time; 3) The target has a new breakthrough in project development or indication
.
The final selected targets are collectively referred to as: Pharmcube Translational Medicine Targets 25 ( Pharmcube Translational Medicine Targets 25; PTMT 25 ).
Pharmcube Translational Medicine Targets 25; PTMT 25
What is the value of the targets we selected in 2020?
What is the value of the targets we selected in 2020? On January 28, 2021, the 2020 TOP25 targets for translational medicine of the medical cube were released for the first time.
Based on the translational medicine data, we selected a total of 4 new targets, 17 targets verified by POC, and 4 targets in project development or development.
Targets for new breakthroughs in indications
.
After a year of precipitation, we were pleasantly surprised to find that many of the TOP25 targets selected in 2020 have achieved milestone progress and blockbuster transaction events
① The selected three new crown targets SARS-CoV-2 S protein/Mpro/Rdrp have made great progress in 2021.
② The selected category is POC-validated M1/M4 receptor agonist + M receptor antagonist.
③ The RIPK1 target that was selected as a new breakthrough in the target category has a blockbuster transaction event: Eli Lilly introduced RIPK1 inhibitor R552 for US$960 million for research and development in the fields of immune and neurodegenerative diseases
④ The GPRC5D target, which was selected as a new breakthrough in the target category, has a blockbuster transaction event: Sanofi has been authorized by Eureka to obtain drug development and commercialization rights other than CART cell therapy.
⑤ The selected category is the ACVR2A target that has passed the POC verification, and a blockbuster acquisition event has occurred: Merck acquired Acceleron, and sotatercept is an important target of the acquisition, improving Merck's PAH product line
In addition to the important progress listed above, many POC-validated target-related clinical results have also been released, and the positive data have enabled companies to carry out a number of core clinical trials one after another to advance the drug development process and get approval for marketing at an early date
